1/Exercise 1:Setting up a Cash Flow Statement Novartis You find below Novartis' income statement for the year ended December 31, 2023 as well as the December 31, 2022 and 2023 balance sheets Assignment Prepare a statement of cash flows for the year ended December 31, 2023, using the indirect method The format of your statement should be detailed and clearly indicate the balances of Net cash flow from operating activities Net cash flow from investing activities Net cash flow from financing activities Net change in cash; Reconciliation with balance sheet figures Novartis income statement for the year ended 31 December 2023 USD mm 57920 Sales COS 18697 39 223 Gross margin 27'461 Selling & administrative expenses Other operating expenses Operating profit 852 10910 Less financial expense 175 Profit before taxes Less Tax on profit (or loss) on ordinary activities 10735 1443 Profit on ordinary activities after taxation 9'292 Novartis Balance sheets as at December 2023 and 2022 USD mm USD USD USD mm mm mm Liabilities & Equity 2022 2022 2023 2023 Assets 5'593 5945 2070 5552 Acc. payables 10051 Other short-term debt 6776 6744 Income tax payable 5657 Other current liabilities 30'542 28004 Total current liabilities 6148 6'687 Cash Acc receivables Inventories Other current assets 9902 7267 6'686 2'459 10443 10985 24'051 26'368 Total current assets Property plant & equipment Goodwill and intangible assets 16939 Loan 77'515 79248 Other non-current liabilities 13'781 17096 18'197 11242 14'172 95'712 96'187 Total non-current liabilities Total non-current asssets 25'414 30'877 Capital stock Treasury shares Retained earnings l'001 1001 -89 73'560 92 68 354 Total equity 74'472 69'263 Total assets 126'254 124'191 Total liabilities & |equity 126'254 124'191 Notes During 2023, Novartis depreciated its Property plant & equipment by USD 6017 mm and amortized goodwill for USD 1733 mm